15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 6 firms covering Cullinan Oncology LLC, 6 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets are tightly clustered, $28.00 to $38.00, so the covering firms are broadly aligned. The average target of $32.67 sits 87% above the current $17.48. The rating mix has stayed broadly stable, with Buy-side ratings easing from 8 to 6 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.86 next quarter toward $-2.53 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS6 ratings
Strong Buy
Strong Buy00%
Buy6100%
Hold00%
Sell00%
Strong Sell00%
Based on 6 analysts giving stock ratings to Cullinan Oncology LLC.
As of Jul, 6 of 6 firms rate CGEM a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
CGEM EPS & revenue forecast
EPS · NEXT QUARTER
$-0.86
Range $-1.09 – $-0.71 · 9 analysts · +12% YoY
Next period, 9 analysts expect Cullinan Oncology LLC to earn $-0.86 a share (range $-1.09 – $-0.71), versus $-0.77 a year earlier. Full-year consensus is $-3.00, growing to $-2.53 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 9 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $17.8M, rising to $40.4M next year.
Top analysts covering Cullinan Oncology LLC
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on CGEM.
#1
JH
Jeffrey Hung
Morgan Stanley · Rank #12
Buy
$28.00+60.2% to target
Overall win rate
61%
+ Follow
#2
Andrew Berens
Leerink Partners · Rank #167
Buy
No targeton CGEM
Overall win rate
50%
+ Follow
#3
RB
Robert Burns
HC Wainwright & Co. · Rank #195
Buy
$30.00+71.7% to target
Overall win rate
38%
+ Follow
#4
EW
Edward White
HC Wainwright & Co. · Rank #241
Buy
$33.00+88.8% to target
Overall win rate
31%
+ Follow
#5
Robert Driscoll
Wedbush · Rank #313
Buy
$37.00+111.7% to target
Overall win rate
30%
+ Follow
CGEM stock forecast FAQ
What is CGEM's average 12-month price target?+
The 6 analysts with a live target average $32.67 for Cullinan Oncology LLC over the next 12 months, ranging from a $38.00 high to a $28.00 low.
Is CGEM stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 6 analyst ratings, 6 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for CGEM?+
The Street-high target is $38.00 (BTIG), and the Street-low is $28.00 (Morgan Stanley). The average of all 6 active targets is $32.67.
How many Wall Street analysts cover CGEM?+
6 analysts have an active rating on Cullinan Oncology LLC, and 6 firms carry a live 12-month price target.
Who is the most accurate analyst covering CGEM?+
Among analysts who currently cover CGEM, Jeffrey Hung of Morgan Stanley has the strongest overall Quantellect track record (Rank #12). Their current call is Buy with a $28.00 target.
What is Cullinan Oncology LLC's projected EPS for next quarter?+
The consensus estimate is $-0.86 per share (range $-1.09 – $-0.71) across 9 analysts. Full-year EPS is projected at $-3.00, rising to $-2.53 the following year.
How much revenue is Cullinan Oncology LLC expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $17.8M, growing to $40.4M next year.
Have analysts been upgrading or downgrading CGEM lately?+
As of Jul, 6 of 6 firms rate CGEM a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their CGEM calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
